Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166138 | 0.87 | NOTUM (0.41) | L3MBTL1NOTUMGAACOMTMAPT | |
| SCHEMBL3182485 | 0.81 | BRD4 (0.44) | L3MBTL1KDM4EALDH1A1NOTUMGAA | |
| SCHEMBL3173168 | 0.79 | L3MBTL1 (0.53) | L3MBTL1KDM4EALDH1A1MAPTMEN1 | |
| SCHEMBL4252487 | 0.78 | ALDH1A1 (0.46) | ALDH1A1GAAMAPTMEN1KMT2A | |
| SCHEMBL3175233 | 0.76 | ALDH1A1 (0.36) | L3MBTL1KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL3175412 | 0.75 | CASP3 (0.43) | — | |
| SCHEMBL16386606 | 0.75 | KDM4E (0.51) | L3MBTL1KDM4EALDH1A1GAAMAPT | |
| SCHEMBL3173095 | 0.73 | CASP3 (0.35) | GAAMAPT | |
| SCHEMBL4254704 | 0.71 | TSHR (0.44) | KDM4EALDH1A1LMNAGAAMAPT | |
| SCHEMBL3179506 | 0.71 | GAA (0.47) | L3MBTL1KDM4EALDH1A1LMNANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079690-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-22 | — | — | EP | claimed |
| WO-2008038251-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-03 | — | — | WO | claimed |
| US-20100016376-A1 | CASPASE INHIBITORS BASED ON PYRIDONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2010-01-21 | — | — | US | disclosed |
| CN-101558041-A | Caspase inhibitors based on pyridone scaffold | LG LIFE SCIENCES LTD (KR) | 2009-10-14 | — | — | CN | disclosed |
| EP-2079690-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-22 | — | — | EP | disclosed |
| EP-2079698-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG Life Sciences Ltd. (KR) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008056898-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008038251-A2 | 3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016376-A1 | CASPASE INHIBITORS BASED ON PYRIDONE SCAFFOLD | CASP1, CASP5, CASP2 | L3MBTL1 1996/4885KDM4E 1345/4885ALDH1A1 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.